Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDS Biotechnology CorpPDSB · Entity 7939 | Director | June 24, 2024 | June 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDS Biotechnology Corp
Report date June 24, 2024 · Filed June 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.86 · Expires 2034-06-24 | Direct | 9,000 |
Reported balance
After 2024-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-24 · Grant · Acquired 9,000 · Balance 9,000 F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2024 Filed Jun 25, 2024 20:05 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001140361-24-031292 · form4.xml · derivative · entry 1 SYKES RICHARD · CIK 0001372810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 21:27 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001140361-23-034832 · form4.xml · derivative · entry 1 SYKES RICHARD · CIK 0001372810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 20:15 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001140361-22-024467 · form4.xml · derivative · entry 1 SYKES RICHARD · CIK 0001372810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 23:03 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001140361-21-021495 · form4.xml · derivative · entry 1 SYKES RICHARD · CIK 0001372810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on June 17, 2022. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:43 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-20-014772 · form4.xml · derivative · entry 1 SYKES RICHARD · CIK 0001372810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 23, 2023. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:30 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantCommon Stock | 384,615 | $1.30 | $499,999.50 |
DisclosureSEC source: 0001140361-20-003646 · form4.xml · nonDerivative · entry 1 SYKES RICHARD · CIK 0001372810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,108 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on February 14, 2020. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:45 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0001127602-19-023240 · form4.xml · derivative · entry 1 SYKES RICHARD · CIK 0001372810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-28 F1 · derivative.exercise_date: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 28, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.